title: [Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
abstract: BACKGROUND
  Post kidney transplantation erythrocytosis is a frequent complication in male subjects. in our experience, it occurs in approximately 20% of transplant patients recciving cyclosporine inununosuppression therapy.
  
  
  METHODS
  Twenty-two patients with post kidney transplantation erythrocytosis were treated using ACE-inhibitors (lisinopril) at a dose of 2-5-5 mg/day for a mean period of 15 months. Owing to tbe onset of collateral effects, 27% of these patients requested the conversion of ACE into angiotensin II receptor antagonists (AII). Twenty out of 22 patients were male (90%).
  
  
  RESULTS
  Treatment resulted in a 15% reduction of hematocrit values compared to basal levels, which remained stable over time. No collateral effects were recorded, either for the kidneys or in terms of hypotension.
  
  
  CONCLUSIONS
  ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like Iosartan at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE).
authors.affiliation: Centro Trapianti di Rene, I Clinica Chirurgica, Policlinico, Università di Catania, Catania, Italy. wmorale@tiscalinet.it
authors.forename: W
authors.initials: W
authors.lastname: Morale
authors.forename: C
authors.initials: C
authors.lastname: Puliatti
authors.forename: P
authors.initials: P
authors.lastname: Veroux
authors.forename: M
authors.initials: M
authors.lastname: Veroux
authors.forename: C
authors.initials: C
authors.lastname: Valvo
authors.forename: D
authors.initials: D
authors.lastname: Cappello
authors.forename: D
authors.initials: D
authors.lastname: Puliatti
authors.forename: L
authors.initials: L
authors.lastname: Francesco
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D011086:Polycythemia / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D017706:Lisinopril